Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
October 04, 2021 07:30 ET
|
Zai Lab Limited
Final data collection is expected in the first half of 2022 SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative...
MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021
September 16, 2021 02:45 ET
|
MacroGenics, Inc.
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
MacroGenics Announces Presentations at ESMO 2021 Virtual Annual Congress
September 12, 2021 19:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Sept. 12, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Global $196.96 Bn Oncology Devices Market to 2025 & 2030: Major Players are Eckert & Ziegler BEBIG, Oncura, GE, Medtronic, Varian Medical Systems, Elekta, Theragenics, Accuray, and Roche Diagnostics
August 20, 2021 06:08 ET
|
Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight
May 04, 2021 20:00 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, May 04, 2021 (GLOBE NEWSWIRE) -- The Plethora of Clinical Trials Explore Gastric Cancer Treatments: A Status Review by DelveInsight The Gastric Cancer pipeline will allow the...
Global Rare Disease Market is estimated to be US$ 547.5 billion by 2030 with a CAGR of 13.1% during the forecast period - by PMI
February 24, 2021 10:35 ET
|
PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Global Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030 and is anticipated to register a CAGR...
Turning Point and Zai Lab Broaden Collaboration
January 11, 2021 06:45 ET
|
Zai Lab Limited; Turning Point Therapeutics, Inc.
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to Receive $25 Million Upfront, with Up to Approximately...
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
October 26, 2020 09:00 ET
|
RedHill Biopharma Ltd.
H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
July 09, 2020 18:43 ET
|
MacroGenics, Inc.
Rockville, MD, July 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
June 05, 2020 07:30 ET
|
MacroGenics, Inc.
Rockville, MD, June 05, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...